Manila Times Business
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Keystone Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering
2h ago
Moderna Launches Moderna Direct with "eCommerce Powered by FFF Enterprises™”
2h ago
ATN International, Inc. Completes Initial Closing on the Sale of its Towers and Updates 2026 Outlook
2h ago
Neuronetics Appoints Robert Greene as Senior Vice President Sales
2h ago